clopidogrel
美 
英
例句
Conclusion The PPI esomeprazole has no significant influence on inhibition of platelet aggregation by clopidogrel.
結論未發現埃索美拉唑對氯吡格雷的抗血小板聚集作用產生明顯影響。
The invention relates to a bisulfate clopidogrel solid preparation, particles and a preparation method thereof.
本發明涉及一種硫酸氫氯吡格雷的固體制劑、其顆粒及其制備方法。
The difference was primarily due to a reduction in the rate of stroke with clopidogrel.
兩組間差異主要源于使用氯吡格雷減低中風發生率。
Patients assigned the clopidogrel loading dose had slightly less platelet reactivity, but it was not significant compared with placebo.
應用負荷劑量氯吡格雷的患者血小板活性稍小，但是和安慰劑組比較沒有明顯差別。
Secondly, for those patients who do not undergo PCI, the standard dose regimen of clopidogrel is sufficient.
其次，對那些未行PCI的患者，標準劑量給藥方案已經足夠；
Cigarette smoking induces CYP1A2 and may, therefore, enhance the conversion of clopidogrel to its active metabolite.
吸煙誘導CYP1A2而且可能因此增強氯吡格雷轉化為其活性代謝產物。
Objectives: We hypothesized that a standardized outpatient clopidogrel desensitization protocol would be safe and effective.
目的：我們假設門診病人標準化氯吡格雷脫敏療法是安全且有效的。
Patients undergoing stent-based PCI should be treated with triple therapy consisting of aspirin, clopidogrel, and warfarin.
植入支架的PCI患者應該應用阿司匹林、氯吡格雷和華法林三聯治療。
Experiment results show that the stability of the clopidogrel bisulfate tablet of the invention is excellent.
實驗表明，本發明的硫酸氫氯吡格雷片劑的穩定性優異。
The combination of aspirin plus clopidogrel is not more effective than clopidogrel alone, but carries a higher bleeding risk.
阿司匹林與氯吡咯雷聯合應用療效不優于氯吡咯雷單獨用藥，但卻有更高的出血風險。
Background: Clopidogrel is an anti-platelet agent which causes an increase in bleeding time.
背景：氯吡格雷是一種導致凝血時間延長的抗血小板藥物。
The rates of adverse cardiovascular events were lowest in patients treated with both clopidogrel and enoxaparin, the investigators report.
并且同時應用氯吡格雷和依諾肝素的患者心血管事件的發生率最低。
Recent mechanistic studies, however, suggest that omeprazole may reduce the inhibitory effect of clopidogrel on platelet aggregation.
然而已有機制研究提出奧美拉唑會降低氯吡格雷抗血小板的療效。
Clopidogrel therapy does have implications for peri-operative blood loss, but hip fracture is a complex and multifactorial condition.
氯吡格雷療法確實與圍手術期的失血有所關聯，但髖部骨折是一種復雜多因素的情況。
Clopidogrel is not superior to aspirin in unselected stroke patients but is superior in patients at high risk of recurrence.
氯吡格雷在非選擇性卒中患者方面不優于阿司匹林，但對于卒中復發率高的患者更有效。
As demonstrated, the combination of aspirin, clopidogrel and oral anticoagulants increase three to five-fold the hemorrhagic risk.
聯合使用阿司匹林、氯吡格雷和口服抗凝藥使出血的風險增加3~5倍。
Long-term clopidogrel therapy after percutaneous coronary intervention: the "Emperors New Clothes"
經皮冠狀動脈介入治療后氯吡格雷長期治療：“皇帝的新裝”
Prolonged antiplatelet therapy with clopidogrel is mandatory after implantation of drug-eluting stents.
長期與氯吡格雷抗血小板治療是強制性植入后藥物涂層支架。
Patients with clopidogrel resistance had high platelet aggregation and were apt to suffer from cardiovascular events.
氯吡格雷抵抗者血小板聚集率高，易發生心血管事件。
Objective To investigate the therapeutic effect of clopidogrel on progressive ischemic cerebral apoplexy.
目的研究氯吡格雷治療進展型缺血性腦卒中的療效。
Objective To observe the influence of proton pump inhibitor(PPI) esomeprazole on antiplatelet effect of clopidogrel.
目的觀察質子泵抑制劑埃索美拉唑是否影響氯吡格雷的抗血小板聚集作用。
Objective: To assess the PPB rate and outcome and identify risk factors associated with PPB in patients taking clopidogrel.
目的：評估服用氯吡格雷病人PPB的發生率，結果以及相關的危險因素。
Clopidogrel is a newer, more expensive, alternative to aspirin which may be used in some patients intolerant of aspirin.
克拉匹多是一種新藥，價格更貴，可用來作為對阿斯匹林過敏病人的替代品。
A brief overview of drug interaction as a risk factor for clopidogrel resistance is given.
簡要概述了藥物相互作用的風險因素，給出氯吡格雷抵抗。
Objective To explore the effect of clopidogrel bisulfate on aspirin resistance (AR) in patients with ischemic cerebrovascular disease.
目的觀察氯吡格雷對缺血性腦血管病患者阿司匹林抵抗（AR）的影響。
One disabling or fatal stroke would be prevented for every approximately 200 patients treated for 1 year with clopidogrel added to aspirin.
對200名病人進行為期一年的氯吡格雷加阿司匹林聯合治療大約可以預防一起致殘或致死性卒中的發生。
The invention also provides a preparation method of the clopidogrel bisulfate tablet.
本發明還提供了所述的硫酸氫氯吡格雷片劑的制備方法。
Background: Response variability to clopidogrel therapy has been demonstrated.
背景：已有研究顯示氯吡格雷治療反應的變異性。
The incidence of clopidogrel resistance was evaluated by the percent reduction of PAGM.
根據PAGM降低程度判斷氯吡格雷抵抗發生率。
Preferred drugs in the order: first choice as clopidogrel, to aspirin second choice, third choice as ticlopidine.
優選藥物的次序為：第一選擇為氯吡格雷，第二選擇為阿司匹林，第三選擇為噻氯匹啶。
In this article, we reviewed the efficacy and security of high-loading-dose of Clopidogrel in Acute Coronary Syndrome.
現就應用高負荷劑量氯吡格雷治療急性冠狀動脈綜合征的有效性和安全性進行綜述。
abstract: Objective To observe the low molecular weight heparin and aspirin and clopidogrel treatment of unstable angina pectoris.
目的觀察氯吡格雷聯合低分子肝素和阿斯匹林治療不穩定型心絞痛的療效。
What is the relationship between clopidogrel resistance and cardiovascular outcome?
氯吡格雷抵抗和心血管結果之間有何關聯？
Background: No data exist about the impact of non responsiveness to clopidogrel on the risk of DES thrombosis.
背景：沒有數據說明關于氯吡格雷無效對藥物洗脫支架血栓形成風險的影響。
But in clinical practice, many patients take aspirin, clopidogrel or warfarin together to prevent blood clots.
但是臨床中許多患者需要同時服用阿司匹林、氯吡格雷、華法林等抗凝藥物預防血栓形成。
Clopidogrel is metabolically activated by several hepatic cytochrome P450 (CYP) isoenzymes, including CYP1A2.
氯吡格雷通過肝臟細胞色素P450（CYP）酶——包括CYP1A2——代謝性激活。
So clopidogrel could be doubly beneficial, he says.
他說，因此氯吡格雷的益處可能也是雙重性的。
According to the above results of optimization, the overall yield of clopidogrel hydrogen sulfate is 39%.
采用上述最佳工藝條件，氯吡格雷硫酸氫鹽的總收率為39%。
I think the issue of clopidogrel resistance is real and it matters, and this drug is a major advance in that regard.
顧問小組成員理查德?卡農博士說，“我認為氯吡格雷抵抗的觀點是真實且緊要的，并且此藥物是在關注下取得的重要進展。”
Study Question: What is the evidence that a platelet rebound exists, and can it be attenuated by clopidogrel tapering?
研究問題：血小板反跳存在的證據是什么？它能通過氯吡格雷逐漸停藥而減弱呢？
